Evidence map›Paper›PMID 27528117›Full record

Trial reportRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2016

Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.

Swetha Sridharan, Allison Steigler, Nigel A Spry, David Joseph, David S Lamb, John H Matthews, Chris Atkinson, Keen-Hun Tai, Gillian Duchesne, David Christie and 3 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Management of bone metastasis in prostate cancer.Journal of bone and mineral metabolism · 2023
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. European journal of nuclear medicine and molecular imaging · 2019
    Article
  15. Article
  16. STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
  17. Article
  18. Oligometastatic carcinoma prostate - An overview of the last decade.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Swetha SridharanCalvary Mater Newcastle, Waratah, Australia.
Allison SteiglerSchool of Medicine and Public Health, University of Newcastle, Australia.
Nigel A SprySir Charles Gairdner Hospital, Perth, Australia.
David JosephSir Charles Gairdner Hospital, Perth, Australia.
David S LambWellington Cancer Centre, New Zealand.
John H MatthewsAuckland Hospital, New Zealand.
Chris AtkinsonSt Georges Cancer Care Centre, Christchurch, New Zealand.
Keen-Hun TaiPeter MacCallum Cancer Centre, Melbourne, Australia.
Gillian DuchesnePeter MacCallum Cancer Centre, Melbourne, Australia.
David ChristieGenesiscare, Tugun, Australia.
John AttiaSchool of Medicine and Public Health, University of Newcastle, Australia; Hunter Medical Research Institute, Newcastle, Australia.
Elizabeth G HollidaySchool of Medicine and Public Health, University of Newcastle, Australia; Hunter Medical Research Institute, Newcastle, Australia.
James W DenhamSchool of Medicine and Public Health, University of Newcastle, Australia. Electronic address: Jim.Denham@newcastle.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt remains unclear whether eradication of oligometastases by stereotactic body radiation therapy or other means will result in cure or prolongation of survival in some cases, or merely provide palliation. We address this issue with prospectively collected progression and treatment data from the TROG 03.04 RADAR randomised controlled trial for men with locally advanced prostate cancer (PC).

methodsThree Fine and Gray competing risk survival models with time-dependent covariates were used to determine whether metastatic progression status at first diagnosis of bony metastases, i.e. number of bony sites involved and presence of prior or simultaneous other sites of progression, impacts on prostate cancer-specific mortality (PCSM) when adjusted for baseline prognostic factors and allocated primary treatment.

resultsBetween 2003 and 2014, 176 of the 1071 subjects developed bone metastases, 152 developed other sites of progression and 91 died of PC. All subjects received secondary treatment using androgen suppression but none received extirpative treatments. The three models found evidence: 1 - of a clear prognostic gradient according to number of bony metastatic sites; 2 - that other sites of progression contributed to PCSM to a lesser extent than bone progression; and 3 - that further bony metastatic progression in men with up to 3 bony metastases had a major impact on PCSM.

conclusionRandomised trials are essential to determine the value of extirpative treatment for oligometastatic bony metastases due to PC.

Indexed as

AgedAndrogen AntagonistsBone Density Conservation AgentsBone NeoplasmsDiphosphonatesDisease ProgressionHumansImidazolesMaleMiddle AgedPrognosisProstatic NeoplasmsRadiosurgeryZoledronic AcidAndrogen AntagonistsBone Density Conservation AgentsDiphosphonatesImidazolesZoledronic AcidAndrogen suppressionBone metastasisOligometastasisProstate cancerRadiotherapy

Identifiers

PMID27528117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.